

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



信銘生命科技集團有限公司
Aceso Life Science Group Limited
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00474)

FURTHER DELAY IN DESPATCH OF CIRCULAR

References are made to (i) the announcement of Aceso Life Science Group Limited (the “**Company**”) dated 4 May 2026 in relation to, among other things, the Subscription Agreement; and (ii) the announcement of the Company dated 26 May 2026 and 2 July 2026 in relation to the delay in despatch of circular (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

As stated in the Announcements, the Company was expected to despatch its circular containing, among other things, (i) further information on the Subscription Agreement and the transactions contemplated thereunder; (ii) a letter from the Independent Board Committee to the Independent Shareholders; and (iii) a letter of advice from the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in respect of the terms of the Subscription Agreement and the issue of the Consideration Shares under Specific Mandate together with a notice convening the EGM by no later than 31 July 2026.

As additional time is required to prepare and incorporate certain information to be included in the circular, the despatch date of the circular will be postponed to a date on or before 30 September 2026.

By Order of the Board
Aceso Life Science Group Limited
Zhiliang Ou
Executive Director

Hong Kong, 5 August 2026

As at the date of this announcement, the board of directors of the Company comprises two executive directors, namely Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; one non-executive director, namely Ms. Jiang Yang; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.